SCHEMBL31268973

SCHEMBL31268973

Cc1ccnc(Cn2c(-c3ccc(N4CC[C@H](C(N)=O)C4)cc3Cl)nc3c(OC4(C)CC4)ncnc32)c1

nearest known ligand 0.38

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 8/20 0.38
▸ CNR1 P21554 5/20 0.34
▸ CNR2 P34972 4/20 0.34
▸ LMNA P02545 2/20 0.33
▸ TP53 P04637 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ SCN5A Q14524 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ ZAP70 P43403 1/20 0.33
▸ NOTUM Q6P988 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31269333 0.94 PIK3CD (0.37) PIK3CDCNR1CNR2LMNAMAPT
SCHEMBL31268739 0.92 NOTUM (0.39) PIK3CDCNR1CNR2NOTUM
SCHEMBL31269231 0.88 PIK3CD (0.36) PIK3CDCNR1CNR2LMNAMAPT
SCHEMBL31268997 0.86 PIK3CD (0.35) PIK3CDCNR1KCNH2SCN5ASCN9A
SCHEMBL31269405 0.84 LRRK2 (0.38) PIK3CDCNR1CNR2KCNH2SCN5A
SCHEMBL31269136 0.84 PIK3CD (0.36) PIK3CDCNR1CNR2KCNH2SCN5A
SCHEMBL31268791 0.84 CNR1 (0.39) PIK3CDCNR1CNR2KCNH2SCN5A
SCHEMBL31269090 0.83 HTR6 (0.35) PIK3CDCNR1KCNH2SCN5ASCN9A
SCHEMBL31269375 0.83 PIK3CD (0.37) PIK3CDCNR1KCNH2SCN5ASCN9A
SCHEMBL30983484 0.83 PIK3CD (0.36) PIK3CDCNR1CNR2KCNH2SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback